Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England

Country Out Of Sync With Other Project Orbis Markets On Gilead Product

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".